CSIMEMPHIS: Long-term Follow-up of Medulloblastoma Survivors That Received Craniospinal Irradiation

Conditions

• Medulloblastoma

Eligibility Criteria

Sex

ALL

Age

N/A - N/A

Healthy Volunteers

Not accepted

Study Details

The study is being done to learn more about the long-term health and well-being of participants treated for medulloblastoma. The study is to decide which evaluations focusing on therapy-related lasting effects (or toxicities) should be considered. Medulloblastoma outcomes have improved with contemporary therapies including modern neurosurgical techniques and risk-adapted radiotherapy and chemotherapy regimens. However, survivors remain at risk for long-term health problems such as neurocognitive deficits, hearing loss, impaired cardiorespiratory fitness and physical performance, cardiac and neuroendocrine dysfunction, musculoskeletal conditions, and infertility.

Key Dates

Start date

Apr 20, 2026

Status verified

Apr 2026

Primary completion

Oct 31, 2030

Completion

Oct 31, 2031

Study Design

Enrollment

184 participants (estimated)

Arms

• Arm: CSIMEMPHIS-only Group
  Participants meeting the CSIMEMPHIS eligibility criteria.
• Arm: BRAINatomy2 Group
  In addition to meeting the eligibility criteria for CSIMEMPHIS, the Brainatomy2 cohort participants must be able to tolerate non-sedated MRI and must not have a history of clinically significant PFS.

Primary Outcome Measure

To describe and compare the long-term health outcomes among medulloblastoma survivors treated with radiation therapy on or according to the SJMB12 protocol with varying craniospinal doses, chemotherapy regimens, and radiation modalities. [ Time Frame: Baseline ]

Central Contacts

• Thomas E Merchant, DO, PhD
  888-226-4343
  [email protected]

Locations (1)

Find similar trials in Memphis, TN

Related Studies

• Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
  PHASE2 · Recruiting · St. Jude Children's Research Hospital · Palo Alto, California
• Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors
  PHASE1 · Recruiting · St. Jude Children's Research Hospital · Memphis, Tennessee
• Digoxin Medulloblastoma Study
  PHASE2 · Recruiting · H. Lee Moffitt Cancer Center and Research Institute · Birmingham, Alabama
• 68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
  PHASE4 · Recruiting · Weill Medical College of Cornell University · New York, New York